Literature DB >> 31797105

IgM-enriched immunoglobulins (Pentaglobin) may improve the microcirculation in sepsis: a pilot randomized trial.

Roberta Domizi1, Erica Adrario1, Elisa Damiani1, Claudia Scorcella1, Andrea Carsetti1, Paolo Giaccaglia1, Erika Casarotta1, Vincenzo Gabbanelli1, Simona Pantanetti1, Elena Lamura2, Silvia Ciucani1, Abele Donati3.   

Abstract

BACKGROUND: Polyclonal or IgM-enriched immunoglobulins may be beneficial during sepsis as an adjuvant immunomodulatory therapy. We aimed to test whether the infusion of IgM-enriched immunoglobulins improves microvascular perfusion during sepsis.
METHODS: Single-centre, randomized, double-blind, placebo-controlled phase II trial including adult patients with a diagnosis of sepsis or septic shock for less than 24 h. Patients received an intravenous infusion of 250 mg/kg (5 mL/kg) per day of IgM-enriched immunoglobulins (Pentaglobin, n = 10) for 72 h or placebo (NaCl 0.9%, n = 9). At baseline and after 24 and 72 h of infusion, the sublingual microcirculation was assessed with Incident Dark Field videomicroscopy. Thenar near-infrared spectroscopy (NIRS) was applied with a vascular occlusion test to assess tissue oxygenation and microvascular reactivity. Levels of interleukin (IL) 1-beta, IL-6, IL-8, IL-10 and tumour necrosis factor alpha were measured in the serum.
RESULTS: The perfused vessel density (PVD) for small vessels (diameter < 20 micron) increased in the Pentaglobin group (from 21.7 ± 4.7 to 25.5 ± 5.1 mm/mm2) and decreased in the placebo group (from 25 ± 5.8 to 20.7 ± 4.1 mm/mm2, p for interaction < 0.001, two-way analysis of variance). The absolute between-group difference at 72 h was 4.77 (standard error 2.34), p = 0.140. The microvascular flow index for small vessels increased at 24 h in the Pentaglobin group (from 2.68 [2.38-2.78] to 2.93 [2.82-3], p < 0.01) and decreased at 72 h in the placebo group (from 2.83 [2.60-2.97] to 2.67 [2.48-2.73], p < 0.05). Changes in general parameters, cytokines and NIRS-derived parameters were similar between the two groups, except for IL-6 and IL-10 that significantly decreased at 72 h only in the Pentaglobin group.
CONCLUSIONS: A 72-h infusion of IgM-enriched immunoglobulins (Pentaglobin) in patients with sepsis or septic shock may be associated with an increase in sublingual microvascular perfusion. Further studies are needed to confirm our findings. Trial registration NCT02655133, www.ClinicalTrials.gov, date of registration 7th January 2016, https://www.clinicaltrials.gov/ct2/show/NCT02655133.

Entities:  

Keywords:  Immunoglobulins; Immunomodulation; Microcirculation; Pentaglobin; Sepsis

Year:  2019        PMID: 31797105     DOI: 10.1186/s13613-019-0609-5

Source DB:  PubMed          Journal:  Ann Intensive Care        ISSN: 2110-5820            Impact factor:   6.925


  5 in total

1.  Pneumolysin induces platelet destruction, not platelet activation, which can be prevented by immunoglobulin preparations in vitro.

Authors:  Kristin Jahn; Stefan Handtke; Raghavendra Palankar; Sabrina Weißmüller; Geraldine Nouailles; Thomas P Kohler; Jan Wesche; Manfred Rohde; Corina Heinz; Axel F Aschenbrenner; Martina Wolff; Jörg Schüttrumpf; Martin Witzenrath; Sven Hammerschmidt; Andreas Greinacher
Journal:  Blood Adv       Date:  2020-12-22

Review 2.  Best-practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis.

Authors:  Axel Nierhaus; Giorgio Berlot; Detlef Kindgen-Milles; Eckhard Müller; Massimo Girardis
Journal:  Ann Intensive Care       Date:  2020-10-07       Impact factor: 6.925

Review 3.  Use of Intravenous Immunoglobulins in Sepsis Therapy-A Clinical View.

Authors:  Dominik Jarczak; Stefan Kluge; Axel Nierhaus
Journal:  Int J Mol Sci       Date:  2020-08-03       Impact factor: 5.923

4.  Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.

Authors:  Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2020-04-05       Impact factor: 9.754

Review 5.  Intravenous immunoglobulin as an important adjunct in the prevention and therapy of coronavirus 2019 disease.

Authors:  Maria Giovanna Danieli; Mario Andrea Piga; Alberto Paladini; Eleonora Longhi; Cristina Mezzanotte; Gianluca Moroncini; Yehuda Shoenfeld
Journal:  Scand J Immunol       Date:  2021-09-16       Impact factor: 3.487

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.